Skip to content
TrialScanner

NCT02674750

Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations

Phase 2CompletedCRISLead

Registry record

Lead sponsor
Curis, Inc.
Conditions
Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations
Primary completion
May 28, 2019Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02674750 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02674750: Study to Evaluate the... | TrialScanner